Edwards Lifesciences Expands Transcatheter Valve Replacement Sector With Innovalve Deal
TD Cowen Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $100
TD Cowen analyst Josh Jennings maintains $Edwards Lifesciences(EW.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 52.8%
TD Cowen Reaffirms Their Buy Rating on Edwards Lifesciences (EW)
Tesla, AT&T, Alphabet, Chipotle, Visa, and More Stocks to Watch This Week
Second-quarter earnings season continues with Verizon, Alphabet, Coca-Cola, Comcast, General Motors, Tesla, Visa, AT&T, Chipotle, and Newmont.
Are Edwards Lifesciences Corporation (NYSE:EW) Investors Paying Above The Intrinsic Value?
Earnings Preview: EW to Report Financial Results Post-market on July 24
$Edwards Lifesciences(EW.US)$ is scheduled to release its financial results post-market on July 24. Earnings PreviewAnalysts estimate $Edwards Lifesciences(EW.US)$ to post revenue of USD1.65 billion
Med-tech and Healthcare Stocks With Upside During 2Q Earnings - Baird
Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions
Is Edwards Lifesciences Corporation (NYSE:EW) Worth US$87.3 Based On Its Intrinsic Value?
Key Insights Edwards Lifesciences' estimated fair value is US$70.02 based on 2 Stage Free Cash Flow to Equity Current share price of US$87.31 suggests Edwards Lifesciences is potentially 25%
Edwards Lifesciences: A Strategic Hold Amid Expansion and Anticipated Clinical Trials
Edwards Lifesciences to Host Earnings Conference Call on July 24, 2024
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2024 after the market closes on Wednesday, July 24, 2024, and
Edwards Lifesciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/16/2024 22.22% Truist Securities $105 → $110 Maintains Buy 07/10/2024 17.78% Citigroup $105 → $106
Truist Financial Maintains Edwards Lifesciences(EW.US) With Buy Rating, Announces Target Price $110
Truist Financial analyst Richard Newitter maintains $Edwards Lifesciences(EW.US)$ with a buy rating, and sets the target price at $110.According to TipRanks data, the analyst has a success rate of 58.
Express News | Edwards Lifesciences Corp : Truist Securities Raises Target Price to $110 From $105
Truist Raises Price Target on Edwards Lifesciences to $110 From $105, Maintains Buy Rating
06:57 AM EDT, 07/16/2024 (MT Newswires) -- Truist Raises Price Target on Edwards Lifesciences to $110 From $105, Maintains Buy RatingPrice: 89.85, Change: +0.35, Percent Change: +0.39
Edwards Lifesciences Buys Mitral Valve Business Innovalve in $300m Deal
BTIG Maintains Edwards Lifesciences(EW.US) With Hold Rating
BTIG analyst Marie Thibault maintains $Edwards Lifesciences(EW.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 32.5% and a total average return of -1.5% over
Maintaining Hold on Edwards Lifesciences Amid Strategic Expansion and Product Development
Sector Update: Health Care Stocks Retreat Monday Afternoon
Health care stocks fell Monday afternoon with the NYSE Health Care Index shedding 0.5% and the Health Care Select Sector SPDR Fund (XLV) down 0.4%.The iShares Biotechnology ETF (IBB) was little
Sector Update: Health
Health care stocks were slipping Monday afternoon, with the NYSE Health Care Index shedding 0.3% and the Health Care Select Sector SPDR Fund (XLV) down 0.4%.The iShares Biotechnology ETF (IBB)